SMi's 9th Annual Pharmaceutical Microbiology UK Conference

SMi Group 20 - 21 January 2020, London, UK.
Pharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing, which has accounted for $3.5 billion last year, while projected to reach nearly double at $6 billion by 2025, and an estimated CAGR of 8.3% leading up to 2025.

At the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring, process automation, and discussing updates to meet regulatory requirements.

Join us at SMi's 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology.

At the 9th Annual Pharmaceutical Microbiology Conference, you will gain insight into

Featured speakers include

  • Luis Meirinhos-Soares, GMP Inspector, Infarmed IP
  • Jim Polarine, Senior Technical Service Manager, STERIS Corporation
  • Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
  • Pratixa Patel, Senior Director, Microbiology and Stability Sciences, GSK
  • Ian Symonds, Pharmaceutical Consultant, SDA Pharma
  • Michael Song, Senior Manager, MedImmune
  • Maria Jose Zafra-Domene, Microbiology QC Team Leader, MeiraGTx
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul Ehrlich Institute

Key highlights include for 2020

  • Discuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products from PHSS
  • Gain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1 revisions on pharmaceutical microbiology
  • Examine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS
  • Explore container closure integrity and controls strategies ensuring product sterility from AstraZeneca
  • Revisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP

View the full agenda: www.pharma-microbiology.com/wpnWL

Early Bird - Rates

  • Book by 31st October and Save £200
  • Book by 29th November and Save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...